The global Transthyretin Amyloidosis Treatment market was valued at million in 2024 and is projected to reach US$ million by 2032, at a CAGR of %during the forecast period.
The growth is attributed to the extensive research in the development of new therapies and the presence of robust pipeline drugs that are used to treat transthyretin.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
We have surveyed the Transthyretin Amyloidosis Treatment companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks
This report aims to provide a comprehensive presentation of the global market for Transthyretin Amyloidosis Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Transthyretin Amyloidosis Treatment. This report contains market size and forecasts of Transthyretin Amyloidosis Treatment in global, including the following market information:
Global Transthyretin Amyloidosis Treatment market revenue, 2020-2025, 2026-2032, ($ millions)
Global top five Transthyretin Amyloidosis Treatment companies in 2024 (%)
Total Market by Segment:
Global Transthyretin Amyloidosis Treatment market, by Type, 2020-2025, 2026-2032 ($ millions)
Global Transthyretin Amyloidosis Treatment market segment percentages, by Type, 2024 (%)
ATTR-PN
ATTR-CM
Global Transthyretin Amyloidosis Treatment market, by Application, 2020-2025, 2026-2032 ($ millions)
Global Transthyretin Amyloidosis Treatment market segment percentages, by Application, 2024 (%)
Hospital Pharmacies
Specialty Pharmacies
Retail Pharmacies
Online Pharmacies
Global Transthyretin Amyloidosis Treatment market, by region and country, 2020-2025, 2026-2032 ($ millions)
Global Transthyretin Amyloidosis Treatment market segment percentages, by region and country, 2024 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Transthyretin Amyloidosis Treatment revenues in global market, 2020-2025 (estimated), ($ millions)
Key companies Transthyretin Amyloidosis Treatment revenues share in global market, 2024 (%)
Further, the report presents profiles of competitors in the market, key players include:
Pfizer Inc.
Johnson & Johnson Services, Inc.
Ionis Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
BridgeBio Pharma, Inc.
Bristol-Myers Squibb Company
Acrotech Biopharma
AstraZeneca
Astellas Pharma, Inc.
Prothena
SOM Biotech
Outline of Major Chapters:
Chapter 1: Introduces the definition of Transthyretin Amyloidosis Treatment, market overview.
Chapter 2: Global Transthyretin Amyloidosis Treatment market size in revenue.
Chapter 3: Detailed analysis of Transthyretin Amyloidosis Treatment company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Transthyretin Amyloidosis Treatment in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.
TABLE OF CONTENTS
1 Introduction to Research & Analysis Reports
1.1 Transthyretin Amyloidosis Treatment Market Definition
1.2 Market Segments
1.2.1 Segment by Type
1.2.2 Segment by Application
1.3 Global Transthyretin Amyloidosis Treatment Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Transthyretin Amyloidosis Treatment Overall Market Size
2.1 Global Transthyretin Amyloidosis Treatment Market Size: 2024 VS 2032
2.2 Global Transthyretin Amyloidosis Treatment Market Size, Prospects & Forecasts: 2020-2032
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Transthyretin Amyloidosis Treatment Players in Global Market
3.2 Top Global Transthyretin Amyloidosis Treatment Companies Ranked by Revenue
3.3 Global Transthyretin Amyloidosis Treatment Revenue by Companies
3.4 Top 3 and Top 5 Transthyretin Amyloidosis Treatment Companies in Global Market, by Revenue in 2024
3.5 Global Companies Transthyretin Amyloidosis Treatment Product Type
3.6 Tier 1, Tier 2, and Tier 3 Transthyretin Amyloidosis Treatment Players in Global Market
3.6.1 List of Global Tier 1 Transthyretin Amyloidosis Treatment Companies
3.6.2 List of Global Tier 2 and Tier 3 Transthyretin Amyloidosis Treatment Companies
4 Sights by Product
4.1 Overview
4.1.1 Segmentation by Type - Global Transthyretin Amyloidosis Treatment Market Size Markets, 2024 & 2032
4.1.2 ATTR-PN
4.1.3 ATTR-CM
4.2 Segmentation by Type - Global Transthyretin Amyloidosis Treatment Revenue & Forecasts
4.2.1 Segmentation by Type - Global Transthyretin Amyloidosis Treatment Revenue, 2020-2025
4.2.2 Segmentation by Type - Global Transthyretin Amyloidosis Treatment Revenue, 2026-2032
4.2.3 Segmentation by Type - Global Transthyretin Amyloidosis Treatment Revenue Market Share, 2020-2032
5 Sights by Application
5.1 Overview
5.1.1 Segmentation by Application - Global Transthyretin Amyloidosis Treatment Market Size, 2024 & 2032
5.1.2 Hospital Pharmacies
5.1.3 Specialty Pharmacies
5.1.4 Retail Pharmacies
5.1.5 Online Pharmacies
5.2 Segmentation by Application - Global Transthyretin Amyloidosis Treatment Revenue & Forecasts
5.2.1 Segmentation by Application - Global Transthyretin Amyloidosis Treatment Revenue, 2020-2025
5.2.2 Segmentation by Application - Global Transthyretin Amyloidosis Treatment Revenue, 2026-2032
5.2.3 Segmentation by Application - Global Transthyretin Amyloidosis Treatment Revenue Market Share, 2020-2032
6 Sights by Region
6.1 By Region - Global Transthyretin Amyloidosis Treatment Market Size, 2024 & 2032
6.2 By Region - Global Transthyretin Amyloidosis Treatment Revenue & Forecasts
6.2.1 By Region - Global Transthyretin Amyloidosis Treatment Revenue, 2020-2025
6.2.2 By Region - Global Transthyretin Amyloidosis Treatment Revenue, 2026-2032
6.2.3 By Region - Global Transthyretin Amyloidosis Treatment Revenue Market Share, 2020-2032
6.3 North America
6.3.1 By Country - North America Transthyretin Amyloidosis Treatment Revenue, 2020-2032
6.3.2 United States Transthyretin Amyloidosis Treatment Market Size, 2020-2032
6.3.3 Canada Transthyretin Amyloidosis Treatment Market Size, 2020-2032
6.3.4 Mexico Transthyretin Amyloidosis Treatment Market Size, 2020-2032
6.4 Europe
6.4.1 By Country - Europe Transthyretin Amyloidosis Treatment Revenue, 2020-2032
6.4.2 Germany Transthyretin Amyloidosis Treatment Market Size, 2020-2032
6.4.3 France Transthyretin Amyloidosis Treatment Market Size, 2020-2032
6.4.4 U.K. Transthyretin Amyloidosis Treatment Market Size, 2020-2032
6.4.5 Italy Transthyretin Amyloidosis Treatment Market Size, 2020-2032
6.4.6 Russia Transthyretin Amyloidosis Treatment Market Size, 2020-2032
6.4.7 Nordic Countries Transthyretin Amyloidosis Treatment Market Size, 2020-2032
6.4.8 Benelux Transthyretin Amyloidosis Treatment Market Size, 2020-2032
6.5 Asia
6.5.1 By Region - Asia Transthyretin Amyloidosis Treatment Revenue, 2020-2032
6.5.2 China Transthyretin Amyloidosis Treatment Market Size, 2020-2032
6.5.3 Japan Transthyretin Amyloidosis Treatment Market Size, 2020-2032
6.5.4 South Korea Transthyretin Amyloidosis Treatment Market Size, 2020-2032
6.5.5 Southeast Asia Transthyretin Amyloidosis Treatment Market Size, 2020-2032
6.5.6 India Transthyretin Amyloidosis Treatment Market Size, 2020-2032
6.6 South America
6.6.1 By Country - South America Transthyretin Amyloidosis Treatment Revenue, 2020-2032
6.6.2 Brazil Transthyretin Amyloidosis Treatment Market Size, 2020-2032
6.6.3 Argentina Transthyretin Amyloidosis Treatment Market Size, 2020-2032
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa Transthyretin Amyloidosis Treatment Revenue, 2020-2032
6.7.2 Turkey Transthyretin Amyloidosis Treatment Market Size, 2020-2032
6.7.3 Israel Transthyretin Amyloidosis Treatment Market Size, 2020-2032
6.7.4 Saudi Arabia Transthyretin Amyloidosis Treatment Market Size, 2020-2032
6.7.5 UAE Transthyretin Amyloidosis Treatment Market Size, 2020-2032
7 Companies Profiles
7.1 Pfizer Inc.
7.1.1 Pfizer Inc. Corporate Summary
7.1.2 Pfizer Inc. Business Overview
7.1.3 Pfizer Inc. Transthyretin Amyloidosis Treatment Major Product Offerings
7.1.4 Pfizer Inc. Transthyretin Amyloidosis Treatment Revenue in Global Market (2020-2025)
7.1.5 Pfizer Inc. Key News & Latest Developments
7.2 Johnson & Johnson Services, Inc.
7.2.1 Johnson & Johnson Services, Inc. Corporate Summary
7.2.2 Johnson & Johnson Services, Inc. Business Overview
7.2.3 Johnson & Johnson Services, Inc. Transthyretin Amyloidosis Treatment Major Product Offerings
7.2.4 Johnson & Johnson Services, Inc. Transthyretin Amyloidosis Treatment Revenue in Global Market (2020-2025)
7.2.5 Johnson & Johnson Services, Inc. Key News & Latest Developments
7.3 Ionis Pharmaceuticals, Inc.
7.3.1 Ionis Pharmaceuticals, Inc. Corporate Summary
7.3.2 Ionis Pharmaceuticals, Inc. Business Overview
7.3.3 Ionis Pharmaceuticals, Inc. Transthyretin Amyloidosis Treatment Major Product Offerings
7.3.4 Ionis Pharmaceuticals, Inc. Transthyretin Amyloidosis Treatment Revenue in Global Market (2020-2025)
7.3.5 Ionis Pharmaceuticals, Inc. Key News & Latest Developments
7.4 Alnylam Pharmaceuticals, Inc.
7.4.1 Alnylam Pharmaceuticals, Inc. Corporate Summary
7.4.2 Alnylam Pharmaceuticals, Inc. Business Overview
7.4.3 Alnylam Pharmaceuticals, Inc. Transthyretin Amyloidosis Treatment Major Product Offerings
7.4.4 Alnylam Pharmaceuticals, Inc. Transthyretin Amyloidosis Treatment Revenue in Global Market (2020-2025)
7.4.5 Alnylam Pharmaceuticals, Inc. Key News & Latest Developments
7.5 BridgeBio Pharma, Inc.
7.5.1 BridgeBio Pharma, Inc. Corporate Summary
7.5.2 BridgeBio Pharma, Inc. Business Overview
7.5.3 BridgeBio Pharma, Inc. Transthyretin Amyloidosis Treatment Major Product Offerings
7.5.4 BridgeBio Pharma, Inc. Transthyretin Amyloidosis Treatment Revenue in Global Market (2020-2025)
7.5.5 BridgeBio Pharma, Inc. Key News & Latest Developments
7.6 Bristol-Myers Squibb Company
7.6.1 Bristol-Myers Squibb Company Corporate Summary
7.6.2 Bristol-Myers Squibb Company Business Overview
7.6.3 Bristol-Myers Squibb Company Transthyretin Amyloidosis Treatment Major Product Offerings
7.6.4 Bristol-Myers Squibb Company Transthyretin Amyloidosis Treatment Revenue in Global Market (2020-2025)
7.6.5 Bristol-Myers Squibb Company Key News & Latest Developments
7.7 Acrotech Biopharma
7.7.1 Acrotech Biopharma Corporate Summary
7.7.2 Acrotech Biopharma Business Overview
7.7.3 Acrotech Biopharma Transthyretin Amyloidosis Treatment Major Product Offerings
7.7.4 Acrotech Biopharma Transthyretin Amyloidosis Treatment Revenue in Global Market (2020-2025)
7.7.5 Acrotech Biopharma Key News & Latest Developments
7.8 AstraZeneca
7.8.1 AstraZeneca Corporate Summary
7.8.2 AstraZeneca Business Overview
7.8.3 AstraZeneca Transthyretin Amyloidosis Treatment Major Product Offerings
7.8.4 AstraZeneca Transthyretin Amyloidosis Treatment Revenue in Global Market (2020-2025)
7.8.5 AstraZeneca Key News & Latest Developments
7.9 Astellas Pharma, Inc.
7.9.1 Astellas Pharma, Inc. Corporate Summary
7.9.2 Astellas Pharma, Inc. Business Overview
7.9.3 Astellas Pharma, Inc. Transthyretin Amyloidosis Treatment Major Product Offerings
7.9.4 Astellas Pharma, Inc. Transthyretin Amyloidosis Treatment Revenue in Global Market (2020-2025)
7.9.5 Astellas Pharma, Inc. Key News & Latest Developments
7.10 Prothena
7.10.1 Prothena Corporate Summary
7.10.2 Prothena Business Overview
7.10.3 Prothena Transthyretin Amyloidosis Treatment Major Product Offerings
7.10.4 Prothena Transthyretin Amyloidosis Treatment Revenue in Global Market (2020-2025)
7.10.5 Prothena Key News & Latest Developments
7.11 SOM Biotech
7.11.1 SOM Biotech Corporate Summary
7.11.2 SOM Biotech Business Overview
7.11.3 SOM Biotech Transthyretin Amyloidosis Treatment Major Product Offerings
7.11.4 SOM Biotech Transthyretin Amyloidosis Treatment Revenue in Global Market (2020-2025)
7.11.5 SOM Biotech Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
LIST OF TABLES & FIGURES
List of Tables
Table 1. Transthyretin Amyloidosis Treatment Market Opportunities & Trends in Global Market
Table 2. Transthyretin Amyloidosis Treatment Market Drivers in Global Market
Table 3. Transthyretin Amyloidosis Treatment Market Restraints in Global Market
Table 4. Key Players of Transthyretin Amyloidosis Treatment in Global Market
Table 5. Top Transthyretin Amyloidosis Treatment Players in Global Market, Ranking by Revenue (2024)
Table 6. Global Transthyretin Amyloidosis Treatment Revenue by Companies, (US$, Mn), 2020-2025
Table 7. Global Transthyretin Amyloidosis Treatment Revenue Share by Companies, 2020-2025
Table 8. Global Companies Transthyretin Amyloidosis Treatment Product Type
Table 9. List of Global Tier 1 Transthyretin Amyloidosis Treatment Companies, Revenue (US$, Mn) in 2024 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Transthyretin Amyloidosis Treatment Companies, Revenue (US$, Mn) in 2024 and Market Share
Table 11. Segmentation by Type � Global Transthyretin Amyloidosis Treatment Revenue, (US$, Mn), 2024 & 2032
Table 12. Segmentation by Type - Global Transthyretin Amyloidosis Treatment Revenue (US$, Mn), 2020-2025
Table 13. Segmentation by Type - Global Transthyretin Amyloidosis Treatment Revenue (US$, Mn), 2026-2032
Table 14. Segmentation by Application� Global Transthyretin Amyloidosis Treatment Revenue, (US$, Mn), 2024 & 2032
Table 15. Segmentation by Application - Global Transthyretin Amyloidosis Treatment Revenue, (US$, Mn), 2020-2025
Table 16. Segmentation by Application - Global Transthyretin Amyloidosis Treatment Revenue, (US$, Mn), 2026-2032
Table 17. By Region� Global Transthyretin Amyloidosis Treatment Revenue, (US$, Mn), 2024 & 2032
Table 18. By Region - Global Transthyretin Amyloidosis Treatment Revenue, (US$, Mn), 2020-2025
Table 19. By Region - Global Transthyretin Amyloidosis Treatment Revenue, (US$, Mn), 2026-2032
Table 20. By Country - North America Transthyretin Amyloidosis Treatment Revenue, (US$, Mn), 2020-2025
Table 21. By Country - North America Transthyretin Amyloidosis Treatment Revenue, (US$, Mn), 2026-2032
Table 22. By Country - Europe Transthyretin Amyloidosis Treatment Revenue, (US$, Mn), 2020-2025
Table 23. By Country - Europe Transthyretin Amyloidosis Treatment Revenue, (US$, Mn), 2026-2032
Table 24. By Region - Asia Transthyretin Amyloidosis Treatment Revenue, (US$, Mn), 2020-2025
Table 25. By Region - Asia Transthyretin Amyloidosis Treatment Revenue, (US$, Mn), 2026-2032
Table 26. By Country - South America Transthyretin Amyloidosis Treatment Revenue, (US$, Mn), 2020-2025
Table 27. By Country - South America Transthyretin Amyloidosis Treatment Revenue, (US$, Mn), 2026-2032
Table 28. By Country - Middle East & Africa Transthyretin Amyloidosis Treatment Revenue, (US$, Mn), 2020-2025
Table 29. By Country - Middle East & Africa Transthyretin Amyloidosis Treatment Revenue, (US$, Mn), 2026-2032
Table 30. Pfizer Inc. Corporate Summary
Table 31. Pfizer Inc. Transthyretin Amyloidosis Treatment Product Offerings
Table 32. Pfizer Inc. Transthyretin Amyloidosis Treatment Revenue (US$, Mn) & (2020-2025)
Table 33. Pfizer Inc. Key News & Latest Developments
Table 34. Johnson & Johnson Services, Inc. Corporate Summary
Table 35. Johnson & Johnson Services, Inc. Transthyretin Amyloidosis Treatment Product Offerings
Table 36. Johnson & Johnson Services, Inc. Transthyretin Amyloidosis Treatment Revenue (US$, Mn) & (2020-2025)
Table 37. Johnson & Johnson Services, Inc. Key News & Latest Developments
Table 38. Ionis Pharmaceuticals, Inc. Corporate Summary
Table 39. Ionis Pharmaceuticals, Inc. Transthyretin Amyloidosis Treatment Product Offerings
Table 40. Ionis Pharmaceuticals, Inc. Transthyretin Amyloidosis Treatment Revenue (US$, Mn) & (2020-2025)
Table 41. Ionis Pharmaceuticals, Inc. Key News & Latest Developments
Table 42. Alnylam Pharmaceuticals, Inc. Corporate Summary
Table 43. Alnylam Pharmaceuticals, Inc. Transthyretin Amyloidosis Treatment Product Offerings
Table 44. Alnylam Pharmaceuticals, Inc. Transthyretin Amyloidosis Treatment Revenue (US$, Mn) & (2020-2025)
Table 45. Alnylam Pharmaceuticals, Inc. Key News & Latest Developments
Table 46. BridgeBio Pharma, Inc. Corporate Summary
Table 47. BridgeBio Pharma, Inc. Transthyretin Amyloidosis Treatment Product Offerings
Table 48. BridgeBio Pharma, Inc. Transthyretin Amyloidosis Treatment Revenue (US$, Mn) & (2020-2025)
Table 49. BridgeBio Pharma, Inc. Key News & Latest Developments
Table 50. Bristol-Myers Squibb Company Corporate Summary
Table 51. Bristol-Myers Squibb Company Transthyretin Amyloidosis Treatment Product Offerings
Table 52. Bristol-Myers Squibb Company Transthyretin Amyloidosis Treatment Revenue (US$, Mn) & (2020-2025)
Table 53. Bristol-Myers Squibb Company Key News & Latest Developments
Table 54. Acrotech Biopharma Corporate Summary
Table 55. Acrotech Biopharma Transthyretin Amyloidosis Treatment Product Offerings
Table 56. Acrotech Biopharma Transthyretin Amyloidosis Treatment Revenue (US$, Mn) & (2020-2025)
Table 57. Acrotech Biopharma Key News & Latest Developments
Table 58. AstraZeneca Corporate Summary
Table 59. AstraZeneca Transthyretin Amyloidosis Treatment Product Offerings
Table 60. AstraZeneca Transthyretin Amyloidosis Treatment Revenue (US$, Mn) & (2020-2025)
Table 61. AstraZeneca Key News & Latest Developments
Table 62. Astellas Pharma, Inc. Corporate Summary
Table 63. Astellas Pharma, Inc. Transthyretin Amyloidosis Treatment Product Offerings
Table 64. Astellas Pharma, Inc. Transthyretin Amyloidosis Treatment Revenue (US$, Mn) & (2020-2025)
Table 65. Astellas Pharma, Inc. Key News & Latest Developments
Table 66. Prothena Corporate Summary
Table 67. Prothena Transthyretin Amyloidosis Treatment Product Offerings
Table 68. Prothena Transthyretin Amyloidosis Treatment Revenue (US$, Mn) & (2020-2025)
Table 69. Prothena Key News & Latest Developments
Table 70. SOM Biotech Corporate Summary
Table 71. SOM Biotech Transthyretin Amyloidosis Treatment Product Offerings
Table 72. SOM Biotech Transthyretin Amyloidosis Treatment Revenue (US$, Mn) & (2020-2025)
Table 73. SOM Biotech Key News & Latest Developments
List of Figures
Figure 1. Transthyretin Amyloidosis Treatment Product Picture
Figure 2. Transthyretin Amyloidosis Treatment Segment by Type in 2024
Figure 3. Transthyretin Amyloidosis Treatment Segment by Application in 2024
Figure 4. Global Transthyretin Amyloidosis Treatment Market Overview: 2024
Figure 5. Key Caveats
Figure 6. Global Transthyretin Amyloidosis Treatment Market Size: 2024 VS 2032 (US$, Mn)
Figure 7. Global Transthyretin Amyloidosis Treatment Revenue: 2020-2032 (US$, Mn)
Figure 8. The Top 3 and 5 Players Market Share by Transthyretin Amyloidosis Treatment Revenue in 2024
Figure 9. Segmentation by Type � Global Transthyretin Amyloidosis Treatment Revenue, (US$, Mn), 2024 & 2032
Figure 10. Segmentation by Type - Global Transthyretin Amyloidosis Treatment Revenue Market Share, 2020-2032
Figure 11. Segmentation by Application � Global Transthyretin Amyloidosis Treatment Revenue, (US$, Mn), 2024 & 2032
Figure 12. Segmentation by Application - Global Transthyretin Amyloidosis Treatment Revenue Market Share, 2020-2032
Figure 13. By Region - Global Transthyretin Amyloidosis Treatment Revenue Market Share, 2020-2032
Figure 14. By Country - North America Transthyretin Amyloidosis Treatment Revenue Market Share, 2020-2032
Figure 15. United States Transthyretin Amyloidosis Treatment Revenue, (US$, Mn), 2020-2032
Figure 16. Canada Transthyretin Amyloidosis Treatment Revenue, (US$, Mn), 2020-2032
Figure 17. Mexico Transthyretin Amyloidosis Treatment Revenue, (US$, Mn), 2020-2032
Figure 18. By Country - Europe Transthyretin Amyloidosis Treatment Revenue Market Share, 2020-2032
Figure 19. Germany Transthyretin Amyloidosis Treatment Revenue, (US$, Mn), 2020-2032
Figure 20. France Transthyretin Amyloidosis Treatment Revenue, (US$, Mn), 2020-2032
Figure 21. U.K. Transthyretin Amyloidosis Treatment Revenue, (US$, Mn), 2020-2032
Figure 22. Italy Transthyretin Amyloidosis Treatment Revenue, (US$, Mn), 2020-2032
Figure 23. Russia Transthyretin Amyloidosis Treatment Revenue, (US$, Mn), 2020-2032
Figure 24. Nordic Countries Transthyretin Amyloidosis Treatment Revenue, (US$, Mn), 2020-2032
Figure 25. Benelux Transthyretin Amyloidosis Treatment Revenue, (US$, Mn), 2020-2032
Figure 26. By Region - Asia Transthyretin Amyloidosis Treatment Revenue Market Share, 2020-2032
Figure 27. China Transthyretin Amyloidosis Treatment Revenue, (US$, Mn), 2020-2032
Figure 28. Japan Transthyretin Amyloidosis Treatment Revenue, (US$, Mn), 2020-2032
Figure 29. South Korea Transthyretin Amyloidosis Treatment Revenue, (US$, Mn), 2020-2032
Figure 30. Southeast Asia Transthyretin Amyloidosis Treatment Revenue, (US$, Mn), 2020-2032
Figure 31. India Transthyretin Amyloidosis Treatment Revenue, (US$, Mn), 2020-2032
Figure 32. By Country - South America Transthyretin Amyloidosis Treatment Revenue Market Share, 2020-2032
Figure 33. Brazil Transthyretin Amyloidosis Treatment Revenue, (US$, Mn), 2020-2032
Figure 34. Argentina Transthyretin Amyloidosis Treatment Revenue, (US$, Mn), 2020-2032
Figure 35. By Country - Middle East & Africa Transthyretin Amyloidosis Treatment Revenue Market Share, 2020-2032
Figure 36. Turkey Transthyretin Amyloidosis Treatment Revenue, (US$, Mn), 2020-2032
Figure 37. Israel Transthyretin Amyloidosis Treatment Revenue, (US$, Mn), 2020-2032
Figure 38. Saudi Arabia Transthyretin Amyloidosis Treatment Revenue, (US$, Mn), 2020-2032
Figure 39. UAE Transthyretin Amyloidosis Treatment Revenue, (US$, Mn), 2020-2032
Figure 40. Pfizer Inc. Transthyretin Amyloidosis Treatment Revenue Year Over Year Growth (US$, Mn) & (2020-2025)
Figure 41. Johnson & Johnson Services, Inc. Transthyretin Amyloidosis Treatment Revenue Year Over Year Growth (US$, Mn) & (2020-2025)
Figure 42. Ionis Pharmaceuticals, Inc. Transthyretin Amyloidosis Treatment Revenue Year Over Year Growth (US$, Mn) & (2020-2025)
Figure 43. Alnylam Pharmaceuticals, Inc. Transthyretin Amyloidosis Treatment Revenue Year Over Year Growth (US$, Mn) & (2020-2025)
Figure 44. BridgeBio Pharma, Inc. Transthyretin Amyloidosis Treatment Revenue Year Over Year Growth (US$, Mn) & (2020-2025)
Figure 45. Bristol-Myers Squibb Company Transthyretin Amyloidosis Treatment Revenue Year Over Year Growth (US$, Mn) & (2020-2025)
Figure 46. Acrotech Biopharma Transthyretin Amyloidosis Treatment Revenue Year Over Year Growth (US$, Mn) & (2020-2025)
Figure 47. AstraZeneca Transthyretin Amyloidosis Treatment Revenue Year Over Year Growth (US$, Mn) & (2020-2025)
Figure 48. Astellas Pharma, Inc. Transthyretin Amyloidosis Treatment Revenue Year Over Year Growth (US$, Mn) & (2020-2025)
Figure 49. Prothena Transthyretin Amyloidosis Treatment Revenue Year Over Year Growth (US$, Mn) & (2020-2025)
Figure 50. SOM Biotech Transthyretin Amyloidosis Treatment Revenue Year Over Year Growth (US$, Mn) & (2020-2025)
